

**BIOCON GROUP**

**FACT SHEET**

**June - 2013**

**Q1 FY 2014 vs. Q1FY 2013**

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED**  
**BALANCE SHEET** (Rs. Crores)

	June 30, 2013	March 31, 2013
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholder's Funds</b>		
(a) Share capital	100	100
(b) Reserves and surplus	2,714	2,595
	<b>2,814</b>	<b>2,695</b>
<b>Minority interest</b>	68	65
<b>Non-current liabilities</b>		
(a) Long-term borrowings	302	164
(b) Deferred tax liability (net)	40	41
(c) Other long-term liabilities	436	424
(d) Long-term provisions	5	4
	<b>783</b>	<b>633</b>
<b>Current liabilities</b>		
(a) Short-term borrowings	72	85
(b) Trade payables	404	345
(c) Other current liabilities	315	347
(d) Short-term provisions	266	246
	<b>1,057</b>	<b>1,023</b>
<b>TOTAL</b>	<b>4,722</b>	<b>4,416</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Fixed assets	1,904	1,811
(b) Good will	12	12
(c) Non-current investments	65	64
(d) Long term loans and advances	275	248
(e) Other non-current assets	47	41
	<b>2,303</b>	<b>2,176</b>
<b>Current assets</b>		
(a) Current Investments	633	522
(b) Inventories	396	398
(c) Trade receivables	583	510
(d) Cash and cash equivalents	652	673
(e) Short term loans and advances	70	81
(f) Other current assets	85	56
	<b>2,419</b>	<b>2,240</b>
<b>TOTAL</b>	<b>4,722</b>	<b>4,416</b>

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED  
PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	Q1 FY 14	Q1 FY 13	Variance	Q4 FY 13	Variance
<b>INCOME</b>					
Biopharmaceuticals *	439	363	21%	379	16%
Branded formulations - India	101	86	17%	85	19%
<b>Total Biopharmaceuticals</b>	<b>540</b>	<b>449</b>	<b>20%</b>	<b>464</b>	<b>16%</b>
Contract research	155	123	26%	166	-7%
<b>Total Sales</b>	<b>695</b>	<b>572</b>	<b>22%</b>	<b>630</b>	<b>10%</b>
Other income	28	22	31%	19	47%
<b>Total Revenue</b>	<b>723</b>	<b>594</b>	<b>22%</b>	<b>649</b>	<b>11%</b>
<b>EXPENDITURE</b>					
Material & Power costs	343	279	23%	310	11%
Staff costs	107	84	28%	99	8%
Research & Development **	43	36	21%	43	-
Other expenses	55	55	-	73	-25%
<b>Manufacturing, staff &amp; other expenses</b>	<b>548</b>	<b>454</b>	<b>21%</b>	<b>525</b>	<b>4%</b>
<b>EBITDA</b>	<b>175</b>	<b>140</b>	<b>26%</b>	<b>124</b>	<b>41%</b>
Interest & Finance charges	-	3		1	
Depreciation & Amortisation	49	43	13%	46	7%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>126</b>	<b>94</b>	<b>36%</b>	<b>77</b>	<b>64%</b>
Exceptional item, Net	-	-	-	202	-
<b>PBT</b>	<b>126</b>	<b>94</b>	<b>36%</b>	<b>279</b>	<b>-55%</b>
Taxes	29	14	117%	28	4%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>97</b>	<b>80</b>	<b>22%</b>	<b>251</b>	<b>-61%</b>
Minority interest	3	-		2	
<b>NET PROFIT FOR THE PERIOD</b>	<b>94</b>	<b>80</b>	<b>19%</b>	<b>249</b>	<b>-62%</b>
<b>EPS Rs.</b>	<b>4.7</b>	<b>3.9</b>		<b>12.4</b>	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>					
* Biopharmaceuticals Income includes:					
Licensing Income	8	14		2	
** Gross Research & Development expenses	46	49		49	